Cantor Fitzgerald Brokers Raise Earnings Estimates for REGN

Key Points

• Cantor Fitzgerald raised its FY2026 EPS estimate for Regeneron Pharmaceuticals from $30.33 to $32.12, though the current consensus estimate is $35.92 per share.
• Regeneron's stock has a consensus rating of "Moderate Buy" with an average target price of $817.46, indicating bullish sentiment among analysts.
• The company recently announced a quarterly dividend of $0.88, reflecting an annualized yield of 0.6%.

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) - Equities researchers at Cantor Fitzgerald boosted their FY2026 EPS estimates for shares of Regeneron Pharmaceuticals in a research note issued to investors on Thursday, October 9th. Cantor Fitzgerald analyst C. Gould now forecasts that the biopharmaceutical company will post earnings of $32.12 per share for the year, up from their prior forecast of $30.33. The consensus estimate for Regeneron Pharmaceuticals' current full-year earnings is $35.92 per share.

A number of other research analysts also recently issued reports on REGN. Truist Financial dropped their target price on shares of Regeneron Pharmaceuticals from $940.00 to $812.00 and set a "buy" rating on the stock in a research report on Monday, August 11th. Wells Fargo & Company downgraded shares of Regeneron Pharmaceuticals from an "overweight" rating to an "equal weight" rating and set a $580.00 target price on the stock. in a research report on Friday, August 1st. Sanford C. Bernstein boosted their target price on shares of Regeneron Pharmaceuticals from $753.00 to $781.00 and gave the company an "outperform" rating in a research report on Wednesday, August 27th. Weiss Ratings restated a "hold (c-)" rating on shares of Regeneron Pharmaceuticals in a report on Wednesday, October 8th. Finally, Citigroup restated a "buy" rating and set a $650.00 price objective on shares of Regeneron Pharmaceuticals in a report on Friday, August 1st. Three equities research analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating, seven have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $817.46.

Regeneron Pharmaceuticals Stock Down 0.9%

Regeneron Pharmaceuticals stock opened at $564.63 on Monday. The company has a quick ratio of 3.72, a current ratio of 4.60 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals has a 12-month low of $476.49 and a 12-month high of $1,024.36. The firm's fifty day moving average is $573.95 and its 200 day moving average is $564.02. The company has a market capitalization of $59.85 billion, a PE ratio of 14.23, a PEG ratio of 1.80 and a beta of 0.31.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last released its earnings results on Friday, August 1st. The biopharmaceutical company reported $12.89 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $8.43 by $4.46. Regeneron Pharmaceuticals had a net margin of 31.37% and a return on equity of 15.06%. The company had revenue of $3.68 billion for the quarter, compared to the consensus estimate of $3.30 billion. During the same quarter in the previous year, the company earned $11.56 EPS. Regeneron Pharmaceuticals's quarterly revenue was up 3.6% compared to the same quarter last year.

Institutional Trading of Regeneron Pharmaceuticals

Institutional investors and hedge funds have recently made changes to their positions in the company. E Fund Management Hong Kong Co. Ltd. raised its holdings in shares of Regeneron Pharmaceuticals by 344.4% in the first quarter. E Fund Management Hong Kong Co. Ltd. now owns 40 shares of the biopharmaceutical company's stock valued at $25,000 after purchasing an additional 31 shares during the last quarter. Activest Wealth Management raised its holdings in shares of Regeneron Pharmaceuticals by 110.5% in the first quarter. Activest Wealth Management now owns 40 shares of the biopharmaceutical company's stock valued at $25,000 after purchasing an additional 21 shares during the last quarter. Costello Asset Management INC purchased a new stake in shares of Regeneron Pharmaceuticals in the first quarter valued at about $27,000. Saudi Central Bank purchased a new stake in shares of Regeneron Pharmaceuticals in the first quarter valued at about $27,000. Finally, Migdal Insurance & Financial Holdings Ltd. purchased a new stake in shares of Regeneron Pharmaceuticals in the second quarter valued at about $31,000. Hedge funds and other institutional investors own 83.31% of the company's stock.

Regeneron Pharmaceuticals Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Wednesday, September 3rd. Stockholders of record on Monday, August 18th were issued a $0.88 dividend. The ex-dividend date was Monday, August 18th. This represents a $3.52 annualized dividend and a dividend yield of 0.6%. Regeneron Pharmaceuticals's dividend payout ratio is currently 8.87%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.